(Q34021572)

30 July 2017

A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study (English)

1 reference

30 July 2017

0 references

0 references

J Proietto

1

1 reference

30 July 2017

A Rissanen

2

1 reference

30 July 2017

J B Harp

3

1 reference

30 July 2017

N Erondu

4

1 reference

30 July 2017

Q Yu

5

1 reference

30 July 2017

S Suryawanshi

6

1 reference

30 July 2017

M E Jones

7

1 reference

30 July 2017

A O Johnson-Levonas

8

1 reference

30 July 2017

S B Heymsfield

9

1 reference

30 July 2017

K D Kaufman

10

1 reference

30 July 2017

J M Amatruda

11

1 reference

30 July 2017

language of work or name

English

0 references

publication date

9 March 2010

1 reference

International Journal of Obesity

30 July 2017

1 reference

30 July 2017

34

1 reference

30 July 2017

8

1 reference

30 July 2017

1243-1254

1 reference

https://scigraph.springernature.com/pub.10.1038/ijo.2010.38

30 July 2017

0 references

cites work

Meta-analysis: pharmacologic treatment of obesity

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.38

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.38

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.38

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.38

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.38

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.38

The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.38

The PHQ-9: validity of a brief depression severity measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.38

Development of a brief measure to assess quality of life in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.38

Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.38

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.38

7 January 2021

Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.38

7 January 2021

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.38

7 January 2021

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2010.38

7 January 2021

Identifiers

DOI

10.1038/IJO.2010.38

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference